Cancer diagnostics firm Biolidics lodges prospectus for Catalist IPO

Singapore

MEDICAL technology firm Biolidics Limited, a cancer diagnostic solutions developer formerly known as Clearbridge Biomedics, lodged a preliminary prospectus on Friday for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board.

Details of the pricing, amount to be raised, and timing of the offering have not yet been announced. UOB is the sponsor, issue manager and placement agent for the IPO.